Skip to main content

Invega Sustenna News

FDA Medwatch Alert: Paliperidone Extended-Release Tablets 3mg by Teva Pharmaceuticals: Recall - Dissolution Test Failure

ISSUE: Teva Pharmaceuticals USA, Inc. (Teva) initiated a voluntary recall to retail-level on 05/31/2017 for one lot of Paliperidone Extended-Release Tablets, 3mg, 90 count bottles, lot 1160682A,...

FDA Approves Invega Trinza (paliperidone palmitate) Four-Times-A-Year Treatment for Schizophrenia

TITUSVILLE, N.J., May 19, 2015 – There’s a new treatment option for schizophrenia – Invega Trinza (three-month paliperidone palmitate), the first and only schizophrenia medication to be administered j...

FDA Approves sNDA for Invega Sustenna (paliperidone palmitate) for Schizoaffective Disorder

TITUSVILLE, N.J., Nov. 13, 2014 /PRNewswire/ – Janssen Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Applications (sNDAs)...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Schizoaffective Disorder, Schizophrenia

Invega Sustenna patient information at Drugs.com